Herpes zoster virus of shingles
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
- ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
- GSK publishes product sales reporting changes and the impact of IFRS 16 ‘Leases’
Tweets from GSK
-
GSK @GSK
It’s been a great week at the #WVCUSA, exploring groundbreaking innovations in vaccine research. Go #BehindTheScience of how advanced tech could potentially help create a cancer vaccine.
about 1 hour ago -
GSK @GSK
“After more than three decades of work and almost $1 billion of investment, GSK and its partners are ready to deploy a vaccine for malaria.” twitter.com/business/statu…
about 20 hours ago
-
GSK @GSK
Antibiotic resistance is on the rise. Can vaccines be part of the solution? Our chief vaccines scientist Rino Rappuoli is talking on this topic today at the #WVCUSA #WorldVaccineCongress #VaccinateForLife
about 4 days ago
